Xeroderma pigmentosum: Outcomes of keratoplasty in Indian pa
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to evaluate the outcomes of keratoplasty for xeroderma pigmentosum (XP) performed at a tertiary eye care center.

A retrospective review of medical records of those patients who were clinically diagnosed to have XP (54 eyes of 36 patients) and underwent keratoplasty; either deep anterior lamellar keratoplasty (DALK, four eyes), endothelial keratoplasty (EK, eight eyes), or penetrating keratoplasty (PK, 42 eyes).

--The median age at surgery was 20.6 years (interquartile range [IQR], 14.6–27.6 years) and 20 were males. Graft failure occurred in 15 eyes in the PK group and two eyes (50%) in the DALK group; none failed in the EK group.

--The probability of graft survival in the PK group was 97.2% ± 2.7% at 1 year, 74.0% ± 8.0% at 2 years, and 54.8% ± 11.7% at 5 years.

--In the PK group, 13 eyes needed antiglaucoma medications, 11 eyes developed graft infiltrate, and 13 eyes needed secondary interventions (cataract surgery, excision biopsy, and tarsorrhaphy).

--In the EK group, three eyes needed secondary interventions (excision biopsy). Median postoperative endothelial cell density at the last follow-up in the PK group was 1214 cells/mm2 (IQR, 623–2277 cells/mm2).

In conclusion, considering the complexities of the ocular surface and adnexal issues in XP, keratoplasty achieved fair results. In the EK party, more than half of the PK grafts survived 5 years with no failures. In addition to solar safety, regular follow-up and prompt treatment of suture-related infections, increased intraocular pressure, and suspected ocular surface lesions are critical for the success of keratoplasty in these eyes.

Source: https://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=4;spage=860;epage=864;aulast=Durgam